MCID: MLG075
MIFTS: 69

Malignant Mesothelioma malady

Cancer diseases, Respiratory diseases categories

Summaries for Malignant Mesothelioma

About this section
Sources:
8Disease Ontology, 46OMIM, 32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Disease Ontology:8 A cell type cancer that has material basis in meothelial tissue.

MalaCards: Malignant Mesothelioma, also known as malignant mesothelioma, susceptibility to, is related to malignant pleural mesothelioma and adenocarcinoma. An important gene associated with Malignant Mesothelioma is MMS (Malignant mesothelioma, susceptibility to), and among its related pathways are FGF signaling pathway and Adhesion. The compounds paraffin and vegf have been mentioned in the context of this disorder. Affiliated tissues include lung, testis and endothelial, and related mouse phenotypes are mortality/aging and cardiovascular system.

Description from OMIM:46 156240

Aliases & Classifications for Malignant Mesothelioma

About this section
Sources:
8Disease Ontology, 9diseasecard, 42NIH Rare Diseases, 22GTR, 46OMIM, 10DISEASES, 44Novoseek, 48Orphanet, 60UMLS, 56SNOMED-CT, 39NCIt, 35MESH via Orphanet, 26ICD10 via Orphanet, 57SNOMED-CT via Orphanet, 61UMLS via Orphanet, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases
Anatomical: Respiratory diseases


Characteristics (Orphanet epidemiological data):

48
mesothelioma:
Inheritance: Sporadic; Prevalence: 1-9/100000; Age of onset: Variable; Age of death: Any age


Aliases & Descriptions:

malignant mesothelioma 8 42 46 10 44 60
malignant mesothelioma, susceptibility to 9 22
advanced malignant mesothelioma 8 60
mesothelioma, malignant 8 42
mesothelioma 48 60
asbestos-related malignant mesothelioma 8
malignant tumor of mesothelium 8
mesothelioma diffuse malignant 44
diffuse malignant mesothelioma 8


External Ids:

Disease Ontology8 DOID:1790
OMIM46 156240
NCIt39 C7865
MESH via Orphanet35 D008654
SNOMED-CT56 62064005
ICD10 via Orphanet26 C45
SNOMED-CT via Orphanet57 62064005
UMLS via Orphanet61 C0025500
ICD1025 C45, C45.9

Related Diseases for Malignant Mesothelioma

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Malignant Mesothelioma family:

Benign Intermediate Mesothelioma Benign Mesothelioma

Diseases related to Malignant Mesothelioma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 253)
idRelated DiseaseScoreTop Affiliating Genes
1malignant pleural mesothelioma31.3CDH2, THBD, MSLN, SPP1, BCL2L1, CEACAM3
2adenocarcinoma31.1CT49, MET, NKX2-1, MUC16, MUC1, CDH2
3malignant peritoneal mesothelioma30.9CALB2
4peritonitis30.8MUC16
5benign mesothelioma30.7SPP1, CALB2, PDPN, WT1, NKX2-1, THBD
6lung adenocarcinoma30.7BCL2L1, CEACAM3, CEACAM5, SPP1, MSLN, TXN
7lung cancer30.6TXN, SFTPB, SOD2, MET, NKX2-1, MSLN
8leukemia30.5BCL2L1, CDH2, WT1
9sarcoma30.4MUC1, MET, WT1, SOD2, CALB2
10melanoma30.3TXN, CALB2, SOD2, PDPN, CT49, MET
11ovarian cancer30.3TXN, CALB2, MET, MUC16, MUC1, CDH2
12adenomatoid tumor30.3CALB2, WT1
13synovial sarcoma30.3CALB2, MET, MUC1
14asbestosis30.3MSLN
15papillary adenocarcinoma30.2NKX2-1, MUC16, MUC1, CEACAM5
16papillary carcinoma30.1CALB2, SOD2, MET, NKX2-1, MUC16, MUC1
17cystadenocarcinoma30.0MUC16, MUC1, CEACAM3, CEACAM5
18squamous cell carcinoma30.0CALB2, SFTPB, SOD2, PDPN, CT49, MET
19breast cancer30.0BAP1, MET, PDPN, SOD2, TXN, MUC16
20lung small cell carcinoma30.0CALB2, CT49, MET, NKX2-1, MUC1, CDH2
21colorectal cancer30.0TXN, PDPN, MET, NKX2-1, BCL2L1, CEACAM3
22non-small cell lung carcinoma30.0SFTPB, MET, NKX2-1, BCL2L1, CEACAM5
23pulmonary alveolar proteinosis30.0SFTPB, MUC1, CEACAM3
24non-hodgkin lymphoma30.0SOD2, CT49, MUC16, BCL2L1
25esophagitis30.0SOD2
26pancreatitis30.0SOD2
27interstitial lung disease30.0MUC1
28hepatitis30.0SOD2
29pericardial effusion30.0MUC16
30hepatocellular carcinoma29.9MET, CT49, SOD2, TXN, NKX2-1, CDH2
31stomach cancer29.9CDH2, MUC1, MET, SOD2, TXN, BCL2L1
32osteosarcoma29.9SPP1, CDH2, MET, CT49
33retinoblastoma29.9BCL2L1, CDH2, CT49, WT1
34endometriosis29.9CDH2, MUC16, CALB2
35angiosarcoma29.9MUC1, PDPN, CALB2
36cervical cancer29.9MUC16, PDPN
37nephrotic syndrome29.9WT1
38glioblastoma multiforme29.7SOD2, PDPN, CT49, MET, CDH2, BCL2L1
39endometrial carcinoma29.7CALB2, NKX2-1, MUC16, CDH2, CEACAM5
40astrocytoma29.7SOD2, CT49, MET, CDH2, SPP1
41thymoma29.7TXN, CALB2, NKX2-1, CEACAM3
42papillary thyroid carcinoma29.7CT49, MET, NKX2-1, SPP1
43hemangioma29.7SFTPB, PDPN, NKX2-1
44renal clear cell carcinoma29.7CALB2, MET, MUC1
45chondrosarcoma29.7CEACAM3, MUC1, MET
46mucinous cystadenocarcinoma29.7CEACAM3, MUC1, MUC16
47cystadenoma29.7CEACAM3
48leiomyoma29.7CDH2
49vasculitis29.7THBD
50ovarian malignant mesothelioma10.5

Graphical network of the top 20 diseases related to Malignant Mesothelioma:



Diseases related to malignant mesothelioma

Clinical Features for Malignant Mesothelioma

About this section
Sources:
46OMIM
See all sources

Clinical features from OMIM:

156240

Drugs & Therapeutics for Malignant Mesothelioma

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Malignant Mesothelioma

Drug clinical trials:

Search ClinicalTrials for Malignant Mesothelioma

Search NIH Clinical Center for Malignant Mesothelioma

Search CenterWatch for Malignant Mesothelioma

Genetic Tests for Malignant Mesothelioma

About this section
Sources:
22GTR
See all sources

Genetic tests related to Malignant Mesothelioma:

id Genetic test Affiliating Genes
1 Mesothelioma, Malignant22

Anatomical Context for Malignant Mesothelioma

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Malignant Mesothelioma:

32
Lung, Testis, Endothelial, Lymph node, T cells, Breast, Testes, Brain, Bone, Colon, Liver, Skin, Thyroid, Pancreas, Placenta, Tongue, Spinal cord, B cells, Monocytes, Kidney, Appendix

Animal Models for Malignant Mesothelioma or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Malignant Mesothelioma:

36
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076811.5TXN, SFTPB, SOD2, PDPN, WT1, MET
2MP:000538511.2SOD2, PDPN, WT1, MET, NKX2-1, BAP1
3MP:000200611.1SOD2, MET, NKX2-1, BAP1, MUC1, SPP1
4MP:000537611.0SPP1, THBD, CDH2, BAP1, PDPN
5MP:000537010.9WT1, MET, MUC1, THBD, SPP1, SOD2
6MP:000537810.9SOD2, PDPN, WT1, MET, NKX2-1, BAP1
7MP:000538810.9SFTPB, PDPN, MET, THBD, SPP1
8MP:000536910.8WT1, MET, BAP1, CDH2, SPP1

Publications for Malignant Mesothelioma

About this section
Sources:
50PubMed
See all sources

Articles related to Malignant Mesothelioma:

(show top 50)    (show all 1576)
idTitleAuthorsYear
1
Pemetrexed Combined with Platinum-based Chemotherapy for Advanced Malignant Peritoneal Mesothelioma: Retrospective Analysis of Six Cases. (24403465)
2014
2
Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma? (23537297)
2013
3
Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers. (23983468)
2013
4
No association between simian virus 40 and diffuse malignant mesothelioma of the pleura in Iranian patients: a molecular and epidemiologic case-control study of 60 patients. (23828611)
2013
5
The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (23456386)
2013
6
Malignant pleural mesothelioma: factors influencing the prognosis. (23413596)
2012
7
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. (22425923)
2012
8
Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. (23977539)
2012
9
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. (23977538)
2012
10
Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. (22497892)
2012
11
The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. (21765044)
2012
12
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma. (22287752)
2012
13
Important recent insights into the genetics and biology of malignant pleural mesothelioma. (23977537)
2012
14
Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. (22223869)
2012
15
Advances in the biology of malignant pleural mesothelioma. (21288646)
2011
16
Interaction of radiation and pemetrexed on a human malignant mesothelioma cell line in vitro. (21868528)
2011
17
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. (21036600)
2011
18
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. (21210110)
2011
19
MicroRNAs dysregulation in human malignant pleural mesothelioma. (21358347)
2011
20
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. (20209622)
2010
21
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? (20338775)
2010
22
Malignant pericardial mesothelioma following thoracal radiotherapy; dissemination from pericardium to pleura. (21038142)
2010
23
Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma. (21505561)
2010
24
Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases. (19618209)
2009
25
Osteopontin is not a specific marker in malignant pleural mesothelioma. (19634115)
2009
26
Malignant pleural mesothelioma in Italy. (20386624)
2009
27
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma. (18996210)
2009
28
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). (19082859)
2009
29
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. (18364248)
2008
30
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. (18827603)
2008
31
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. (18698027)
2008
32
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. (18281122)
2008
33
Clear cell sarcoma mimicking malignant pleural mesothelioma. (18671803)
2008
34
Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. (17383050)
2007
35
Primary malignant peritoneal mesothelioma associated with Metsovo lung. (17696098)
2007
36
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. (16456138)
2006
37
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. (16169910)
2005
38
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. (15276492)
2004
39
Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. (12713628)
2003
40
c-Kit is not expressed in malignant mesothelioma. (12920227)
2003
41
Congenital malignant peritoneal mesothelioma. (12599320)
2003
42
Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. (12684666)
2003
43
SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. (11862420)
2002
44
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. (12015746)
2002
45
Inactivation of p16INK4a expression in malignant mesothelioma by methylation. (12399123)
2002
46
Structure and refinement of the physical mapping of the gamma- glutamylcysteine ligase regulatory subunit (GLCLR) gene to chromosome 1p22.1 within the critically deleted region of human malignant mesothelioma. (9841137)
1998
47
Importance of serum CA 125 levels in malignant peritoneal mesothelioma. (7501967)
1996
48
Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. (7534025)
1995
49
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. (7923195)
1994
50
Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125. (1710413)
1991

Genetic Variations for Malignant Mesothelioma

About this section

Expression for genes affiliated with Malignant Mesothelioma

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Malignant Mesothelioma

Search GEO for disease gene expression data for Malignant Mesothelioma.

Pathways for genes affiliated with Malignant Mesothelioma

About this section
Sources:
37NCBI BioSystems Database, 4Cell Signaling Technology
See all sources

Pathways related to Malignant Mesothelioma according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.7SPP1, CDH2, MET
210.7CEACAM5, CDH2, MUC1

Compounds for genes affiliated with Malignant Mesothelioma

About this section
Sources:
44Novoseek, 59Tocris Bioscience, 28IUPHAR, 11DrugBank, 24HMDB, 49PharmGKB, 2BitterDB
See all sources

Compounds related to Malignant Mesothelioma according to GeneCards/GeneDecks:

(show top 50)    (show all 87)
idCompoundScoreTop Affiliating Genes
1paraffin4412.1CEACAM3, SOD2, SFTPB, CALB2, PDPN, WT1
2vegf4412.1SOD2, PDPN, WT1, CT49, MET, MUC16
3tyrosine4412.0SPP1, PDPN, CALB2, MUC16, SFTPB, WT1
4progesterone44 59 28 11 2415.9CEACAM5, CEACAM3, SPP1, THBD, CDH2, MUC1
5cysteine4411.8MUC1, CDH2, SOD2, SPP1, BCL2L1, CEACAM5
6b 7234411.7NKX2-1, CEACAM5, CEACAM3, MSLN, THBD, CDH2
7retinoic acid44 2412.7CDH2, MUC1, NKX2-1, TXN, SFTPB, CT49
8testosterone44 59 11 2414.6CDH2, CT49, SPP1, TXN, CALB2, SOD2
9oligonucleotide4411.5MET, SPP1, MSLN, THBD, CDH2, NKX2-1
10hyaluronic acid44 2412.5MUC16, SPP1, MSLN, THBD, CEACAM5, MUC1
11actinomycin d4411.5BCL2L1, TXN, SFTPB, SOD2, MET, MUC1
12dexamethasone44 49 28 1114.5SFTPB, CDH2, MUC16, BCL2L1, TXN, SPP1
13doxorubicin44 49 1113.5WT1, SOD2, MUC16, CEACAM3, BCL2L1, TXN
14thymidine44 2412.4CEACAM5, CEACAM3, MUC1, CALB2, CT49, WT1
15cisplatin44 49 59 1114.4SPP1, TXN, SOD2, MET, MUC16, MUC1
16hematoxylin4411.4CALB2, PDPN, NKX2-1, MUC16, CEACAM5, MUC1
17nitric oxide44 11 2413.4THBD, MUC1, MET, WT1, SOD2, SFTPB
18adriamycin4411.4MUC1, BCL2L1, SOD2, TXN, CEACAM5, CEACAM3
19threonine4411.4MET, SPP1, WT1, SFTPB, MUC1, MUC16
20serine4411.4NKX2-1, CT49, WT1, CDH2, MUC16, SFTPB
21ribonucleic acid4411.4SFTPB, MET, NKX2-1, MUC1, SPP1, CEACAM5
22steroid4411.4THBD, CT49, NKX2-1, MUC16, CALB2, CEACAM3
23agar4411.4SOD2, TXN, CT49, MET, SPP1, CEACAM5
24atp44 2812.3BCL2L1, SFTPB, SOD2, CT49, MET, CDH2
25lactate4411.3TXN, SOD2, MUC16, THBD, SPP1, CEACAM3
26gold4411.3CEACAM3, CEACAM5, PDPN, MUC1, MUC16, SFTPB
27creatinine4411.3CEACAM3, THBD, MUC16, WT1, TXN, SPP1
28mucicarmine4411.3NKX2-1, CEACAM3, CEACAM5, MUC1, CALB2
29matrigel4411.3SPP1, THBD, BCL2L1, CDH2, MUC1, MET
30cholesterol44 28 11 2414.3SPP1, THBD, MUC1, SFTPB, MET, CEACAM3
31vitamin d4411.3TXN, SOD2, WT1, MET, THBD, SPP1
32glucose4411.2MET, MUC16, MUC1, THBD, CDH2, CEACAM3
33oxygen44 2412.2TXN, MET, CEACAM3, MUC1, BCL2L1, SFTPB
34curcumin4411.2BCL2L1, SPP1, SOD2, THBD, WT1
35mptp4411.1SOD2, SPP1, BCL2L1, TXN
36lipid4411.1THBD, CDH2, MUC1, MET, CEACAM5, SFTPB
37sialic acid4411.1CDH2, CEACAM3, CEACAM5
385fluorouracil4411.0MUC1, CEACAM5, CEACAM3, SOD2, BCL2L1
39chloramphenicol44 2 1113.0MUC1, TXN, THBD, WT1, SFTPB
40manganese superoxide4411.0BCL2L1, SOD2, SFTPB, TXN
41arginine4411.0SOD2, SFTPB, MET, TXN, WT1, THBD
42estrogen4411.0CALB2
43pdtc4411.0SFTPB, SOD2, MET, BCL2L1
44butyrate4411.0SOD2, CALB2
45cycloheximide4410.9SFTPB, SOD2
46retinoid4410.9SPP1, BCL2L1, THBD, SFTPB, TXN
47alanine4410.9THBD, TXN, SPP1, SOD2, CT49, CEACAM3
48metronidazole44 1111.8CEACAM3, MUC1, CEACAM5
49bleomycin44 1111.7SFTPB
50ascorbic acid44 2411.5SOD2, SFTPB, TXN, SPP1, THBD

GO Terms for genes affiliated with Malignant Mesothelioma

About this section
Sources:
16Gene Ontology
See all sources

Biological processes related to Malignant Mesothelioma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1response to hyperoxiaGO:05509310.6PDPN, SOD2
2response to selenium ionGO:01026910.3SOD2, TXN

Products for genes affiliated with Malignant Mesothelioma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Malignant Mesothelioma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet